V. Guss

发表

Tau transgenic mice as models for cerebrospinal fluid tau biomarkers.

M. Ahlijanian, C. Albright, P. Wes, 2011, Journal of Alzheimer's disease : JAD.

Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor

David W. Smith, J. Hendrick, T. Verdoorn, 2005, Journal of Pharmacology and Experimental Therapeutics.

2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of γ-secretase

David W. Smith, D. Barten, C. Polson, 2004 .

P-Glycoprotein Efflux and Other Factors Limit Brain Amyloid β Reduction by β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors in Mice

J. Macor, J. Marcinkeviciene, M. Ford, 2008, Journal of Pharmacology and Experimental Therapeutics.

2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitors.

J. Macor, D. Barten, C. Polson, 2012, Bioorganic & medicinal chemistry letters.

Nitrogen-appended N-alkylsulfonamides as inhibitors of γ-secretase

David W. Smith, I. Bursuker, D. Barten, 2008 .

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies

A. Cacace, J. Macor, Tai-Hsien Ou Yang, 2022, Molecular therapy. Nucleic acids.

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

Robert J. Neely, K. Blennow, H. Soares, 2013, PloS one.

Viable mouse gene ablations that robustly alter brain Aβ levels are rare

J. Corradi, C. Albright, J. Toyn, 2010, BMC Neuroscience.

Measurement of Aβ1–42 in cerebrospinal fluid is influenced by matrix effects

K. Blennow, H. Zetterberg, N. Andreasen, 2012, Journal of neurochemistry.

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780

J. Macor, M. Ahlijanian, Joseph L. Cantone, 2014, International journal of Alzheimer's disease.

Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects

H. Soares, J. Macor, M. Ahlijanian, 2016, The Journal of Pharmacology and Experimental Therapeutics.

An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning

V. Gribkoff, D. Barten, C. Polson, 2003, Journal of Pharmacology and Experimental Therapeutics.

Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat

H. Feldman, J. Macor, R. Berman, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.

J. Hendrick, T. Verdoorn, D. Barten, 2005, The Journal of pharmacology and experimental therapeutics.

Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

H. Soares, J. Kramer, H. Rosen, 2014, Journal of Neurology, Neurosurgery & Psychiatry.

Utility of high resolution accurate mass spectrometry (HRMS) in the mass isotopomer distribution analysis (MIDA) of CSF proteins modified by stable isotope labeling in mammals (SILAM) methodology applied to neurodegenerative diseases

M. Ahlijanian, Joseph L. Cantone, D. Drexler, 2017 .

Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.

David W. Smith, J. Hendrick, D. Barten, 2007, Bioorganic & medicinal chemistry letters.

P2-346: PGP efflux and other factors limit brain Aβ reduction by BACE1 inhibitors in mice

J. Macor, J. Marcinkeviciene, M. Ford, 2008, Alzheimer's & Dementia.

Effects of neuropeptide Y (NPY) and [d-Trp32]NPY on monoamine and metabolite levels in dialysates from rat hypothalamus during feeding behavior

V. Guss, C. Korpinen, F. Matos, 1996, Neuropeptides.

JPET # 199356 3 Recommended section assignment to guide listing in table of contents : Neuropharmacology

H. Feldman, J. Macor, R. Berman, 2012 .

Amino-caprolactam derivatives as γ-secretase inhibitors

J. Toyn, D. Barten, C. Polson, 2007 .

N -(5 -Chloro -2-(hydroxymethyl)-N -alkyl -arylsulfonamides as γ-secretase inhibitors

David W. Smith, M. Deshpande, D. Barten, 2007 .